Special Drug Use Investigation of EYLEA for AMD
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 25 May 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Sponsors Bayer
- 21 Feb 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 21 Feb 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
- 16 Dec 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.